-$0.02 EPS Expected for Alliqua Biomedical Inc (ALQA) This Quarter

Share on StockTwits

Wall Street analysts forecast that Alliqua Biomedical Inc (NASDAQ:ALQA) will post earnings per share of ($0.02) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Alliqua Biomedical’s earnings. Alliqua Biomedical reported earnings of ($0.79) per share during the same quarter last year, which indicates a positive year over year growth rate of 97.5%. The firm is scheduled to issue its next quarterly earnings report on Thursday, November 8th.

On average, analysts expect that Alliqua Biomedical will report full-year earnings of $5.14 per share for the current financial year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.09) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Alliqua Biomedical.

Alliqua Biomedical (NASDAQ:ALQA) last posted its earnings results on Friday, August 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.64). The business had revenue of $0.86 million during the quarter. Alliqua Biomedical had a negative net margin of 99.08% and a negative return on equity of 169.35%.

Shares of ALQA stock traded down $0.03 on Friday, hitting $2.37. 281 shares of the stock were exchanged, compared to its average volume of 17,640. The stock has a market capitalization of $11.56 million, a P/E ratio of -0.36 and a beta of 1.12. Alliqua Biomedical has a fifty-two week low of $1.58 and a fifty-two week high of $4.50.

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.

Featured Story: Market Capitalization and Individual Investors

Get a free copy of the Zacks research report on Alliqua Biomedical (ALQA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.